RBC Life Sciences Inc. announced unaudited consolidated earnings results for the year ended December 31, 2013. For the year ended, the company reported net sales of $25.5 million, a 1% increase over 2012 consolidated net sales of $25.2 million. The company reported a net loss of $500,000, or $0.23 per diluted share, compared to a net loss of $361,000, or $0.16 per diluted share, during 2012.

Operating loss was $625,000 compared to $464,000 in the same period last year. Loss before income taxes was $736,000 compared to $590,000 in the same period last year.